Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives.

The function of () in human cancer has not been thoroughly or comprehensively examined. Here, we identified the tumor suppressor part of across cancers, including epithelial ovarian tumors. Our study carefully contrasted the expression of VASH1 in pancancer and nontumorous tissues in a public database to explore its regulatory role in clinical prognosis, diagnosis, tumor purity, and immune cell infiltration. Next, we explored the antitumor mechanism of through drug sensitivity, functional enrichment, and phenotypic experiments in ovarian cancer. Research suggests that the expression of in neoplastic tissues is lower than that in normal tissues. affects the OS and RFS of several tumor types. In addition, expression resulted in a high OS and RFS in the diagnosis of tumor and nontumor tissues and negatively regulated tumor purity. Moreover, controls the tumor microenvironment by regulating immunocyte infiltration. In ovarian cancer, can serve as a biomarker to estimate the efficacy of chemotherapy. Functional enrichment analysis suggests that plays a tumor suppressor role by regulating the extracellular matrix receptor pathway. inhibition of the malignant phenotype of ovarian cancer cells was further confirmed by experiments. These results indicate that acts as a cancer-inhibiting factor and potential therapeutic target in ovarian cancer.